company background image
ENTA logo

Enanta Pharmaceuticals NasdaqGS:ENTA Stock Report

Last Price

US$16.53

Market Cap

US$349.7m

7D

14.0%

1Y

-59.0%

Updated

27 Mar, 2024

Data

Company Financials +

Enanta Pharmaceuticals, Inc.

NasdaqGS:ENTA Stock Report

Market Cap: US$349.7m

ENTA Stock Overview

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases.

ENTA fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Enanta Pharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Enanta Pharmaceuticals
Historical stock prices
Current Share PriceUS$16.53
52 Week HighUS$41.45
52 Week LowUS$8.08
Beta0.45
1 Month Change17.74%
3 Month Change69.36%
1 Year Change-58.95%
3 Year Change-66.48%
5 Year Change-82.69%
Change since IPO-3.78%

Recent News & Updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Recent updates

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24
We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08
Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25
Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Oct 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta starts mid-stage trial of EDP-938 for RSV infection

Oct 03

Enanta Pharma FQ3 2022 Earnings Preview

Aug 07

Enanta potential COVID drug shows safety in healthy people in early-stage trial

Jul 29

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04
Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04
Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25
Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Enanta Pharmaceuticals, Inc. 2021 Q1 - Results - Earnings Call Presentation

May 07

Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts

Feb 11
Analysts Just Made A Noticeable Upgrade To Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Forecasts

Enanta Pharma is up after J.P. Morgan upgrade

Jan 29

Shareholder Returns

ENTAUS BiotechsUS Market
7D14.0%0.9%0.4%
1Y-59.0%10.3%28.8%

Return vs Industry: ENTA underperformed the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: ENTA underperformed the US Market which returned 29.5% over the past year.

Price Volatility

Is ENTA's price volatile compared to industry and market?
ENTA volatility
ENTA Average Weekly Movement8.9%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: ENTA's share price has been volatile over the past 3 months.

Volatility Over Time: ENTA's weekly volatility (9%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
1995145Jay Lulyhttps://www.enanta.com

Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir.

Enanta Pharmaceuticals, Inc. Fundamentals Summary

How do Enanta Pharmaceuticals's earnings and revenue compare to its market cap?
ENTA fundamental statistics
Market capUS$349.71m
Earnings (TTM)-US$138.24m
Revenue (TTM)US$73.62m

4.8x

P/S Ratio

-2.5x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ENTA income statement (TTM)
RevenueUS$73.62m
Cost of RevenueUS$0
Gross ProfitUS$73.62m
Other ExpensesUS$211.86m
Earnings-US$138.24m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

May 06, 2024

Earnings per share (EPS)-6.53
Gross Margin100.00%
Net Profit Margin-187.77%
Debt/Equity Ratio0.7%

How did ENTA perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.